Romidepsin: Evidence for its potential use to manage previously treated cutaneous T cell lymphoma

Brian Poligone, Janet Lin, Catherine Chung

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and Sézary syndrome. Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL. Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia. Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCore Evidence
Volume6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Cutaneous T-Cell Lymphoma
Mycosis Fungoides
Histone Deacetylase Inhibitors
Therapeutics
Dysgeusia
Anorexia
Skin Neoplasms
romidepsin
Treatment Failure
Nausea
Vomiting
Fatigue
Leukemia
Apoptosis
T-Lymphocytes
Safety
Growth

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Reviews and References, Medical
  • Pharmacology

Cite this

Poligone, Brian ; Lin, Janet ; Chung, Catherine. / Romidepsin : Evidence for its potential use to manage previously treated cutaneous T cell lymphoma. In: Core Evidence. 2011 ; Vol. 6. pp. 1-12.
@article{9d01d36924774cc288de36fc44c16457,
title = "Romidepsin: Evidence for its potential use to manage previously treated cutaneous T cell lymphoma",
abstract = "Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and S{\'e}zary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and S{\'e}zary syndrome. Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL. Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34{\%} with a partial response of 28{\%} and complete response rate of 6{\%}. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia. Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.",
author = "Brian Poligone and Janet Lin and Catherine Chung",
year = "2011",
month = "12",
day = "1",
doi = "10.2147/CE.S9084",
language = "English (US)",
volume = "6",
pages = "1--12",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",

}

Romidepsin : Evidence for its potential use to manage previously treated cutaneous T cell lymphoma. / Poligone, Brian; Lin, Janet; Chung, Catherine.

In: Core Evidence, Vol. 6, 01.12.2011, p. 1-12.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Romidepsin

T2 - Evidence for its potential use to manage previously treated cutaneous T cell lymphoma

AU - Poligone, Brian

AU - Lin, Janet

AU - Chung, Catherine

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and Sézary syndrome. Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL. Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia. Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.

AB - Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and Sézary syndrome. Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL. Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia. Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=84865378954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865378954&partnerID=8YFLogxK

U2 - 10.2147/CE.S9084

DO - 10.2147/CE.S9084

M3 - Review article

C2 - 21468238

AN - SCOPUS:84865378954

VL - 6

SP - 1

EP - 12

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

ER -